Oruka Therapeutics (NASDAQ:ORKA) Hits New 52-Week Low – Should You Sell?

Oruka Therapeutics, Inc. (NASDAQ:ORKA) shares reached a new 52-week low during mid-day trading on Monday . The company traded as low as $17.64 and last traded at $17.87, with a volume of 16264 shares trading hands. The stock had previously closed at $19.01.

Wall Street Analysts Forecast Growth

ORKA has been the subject of a number of recent research reports. Lifesci Capital began coverage on Oruka Therapeutics in a research note on Monday, September 16th. They issued an “outperform” rating and a $41.00 target price for the company. Wedbush restated an “outperform” rating and issued a $40.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday, November 19th. Stifel Nicolaus began coverage on shares of Oruka Therapeutics in a research report on Friday, October 11th. They set a “buy” rating and a $49.00 target price on the stock. HC Wainwright reissued a “buy” rating and issued a $45.00 price target on shares of Oruka Therapeutics in a research report on Friday, December 20th. Finally, Leerink Partnrs raised Oruka Therapeutics to a “strong-buy” rating in a report on Tuesday, September 17th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $43.17.

Oruka Therapeutics Price Performance

The firm has a market capitalization of $632.08 million, a price-to-earnings ratio of -2.88 and a beta of 0.78. The firm has a fifty day moving average of $23.74.

Institutional Trading of Oruka Therapeutics

Several large investors have recently made changes to their positions in the business. Geode Capital Management LLC bought a new position in shares of Oruka Therapeutics in the third quarter valued at about $343,000. The Manufacturers Life Insurance Company bought a new position in shares of Oruka Therapeutics in the third quarter worth about $1,037,000. Wellington Management Group LLP acquired a new position in shares of Oruka Therapeutics during the third quarter worth approximately $2,013,000. Janus Henderson Group PLC acquired a new position in shares of Oruka Therapeutics during the third quarter worth approximately $5,840,000. Finally, Redmile Group LLC bought a new stake in shares of Oruka Therapeutics during the third quarter valued at approximately $10,091,000. Institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.